Skip to main content

Table 1 (abstract P95). Baseline characteristics and interim analysis data of patients with HIDS

From: Proceedings of the 27th European Paediatric Rheumatology Congress (PReS 2021)

 

Baseline (N=7)

6 months (N=6)

12 months (N=4)

Number (%*) of patients in disease remission (physician assessment)

4 (57.1)

5 (83,3)

3 (75.0)

Physician Global Assessment, percentage of absent/mild-moderate/severe rating

43 / 43 / 14

83 / 17 / 0

50 / 50 / 0

Patients´ assessment of current disease activity; 0–10, median (min; max)

0 (0; 7)

1.0 (0; 3)

0.5 (0; 8)

Patients´ assessment of current fatigue; 0–10, median (min; max)

2.0 (0; 7)

1.5 (0; 7)

2.5 (0; 4)

Number (%*) of patients without impairment of social life by the disease

2 (40)

4 (80)

3 (100)

Number (%*) of patients with days absent from work/school during last 6 months

2 (29)

3 (50)

0 (0)

CRP, median (mg/dl)

0.2

0.5

0.3

SAA, median (mg/dl)

0.6

0.9

0.8

  1. CRP c-reactive protein, SAA serum amyloid A
  2. *not reported for all patients